•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Natuzzi Announces Resignation of a Board Member, Pietro Labriola
Natuzzi Announces Resignation of a Board Member, Pietro Labriola
The NYSE Accepts Natuzzi's Plan to Regain Compliance with Continued Listing Standards
Natuzzi S.p.A. (NTZ) Q4 2025 Earnings Call Transcript
Natuzzi Filed Its Annual Report on Form 20-F With the SEC
Natuzzi Announces Financial Results for the Fourth Quarter of 2025
Natuzzi Filed Form 12B-25 for Late Filing of Form 20-F
Natuzzi (NYSE:NTZ) Share Price Passes Above 50 Day Moving Average – Here’s What Happened
Natuzzi (NYSE:NTZ) Share Price Crosses Below Two Hundred Day Moving Average – Here’s Why
GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF
Ordinary Shareholders' Meeting of Natuzzi S.p.A.
Natuzzi Received Continued Listing Standard Notice From the NYSE
Natuzzi S.p.A. (NTZ) Q3 2025 Earnings Call Transcript
Natuzzi Announces Financial Results for the Third Quarter of 2025
Financial Survey: Maxx Sports TV (OTCMKTS:AMXX) versus Natuzzi (NYSE:NTZ)
Natuzzi S.p.A. Announces Dates for Its 2025 Third Quarter and First Nine Months Financial Information and Conference Call
Natuzzi S.p.A. (NTZ) Q2 2025 Earnings Call Transcript
Natuzzi Announces Financial Results for the Second Quarter of 2025
Natuzzi S.p.A. Announces Dates for Its 2025 Second Quarter and First Half Financial Information and Conference Call
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025